1. Федеральные клинические рекомендации (протоколы) по ведению детей с эндокринными заболеваниями. Под ред. И.И. Дедова и В.А. Петерковой. - М.: Практика, 2014. - 442 стр.
2. Дедов И.И, Мельниченко Г.А. Эндокринология. Национальное руководство, Краткое издание М. :ГЭОТАР-Медиа, 2013.
3. Bergman P., Auldist A. W., Cameron F. Review of the outcome of management of Graves’ disease in children and adolescents. J Paediatr Child Health 2001; 37:176—182.
4. Дедов И.И., Мельниченко Г.А., Беловалова И.М. и соавт. Федеральные клинические рекомендации по диагностике и лечению эндокринной офтальмопатии при аутоиммунной патологии щитовидной железы.; Москва; 2014
5. Krassas G.E., Segni M., Wiersinga W.M. Childhood Graves' ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol. 2005 Oct; 153(4):515-21.
6. Йододефицитные заболевания у детей и подростов: диагностика, лечение, профилактика/ Научно-практическая программа / М.: Международный фонд охраны здоровья матери и ребнка 2005, 48с
7. Gogakos A.I., Boboridis K., Krassas G.E. Pediatric aspects in Graves' orbitopathy. Pediatr Endocrinol Rev. 2010 Mar; 7 Suppl 2():234-44.
8. Justyna Szczapa-Jagustyn, Anna Gotz-Wieckowska, Jaroslaw Kociecki An update on thyroid-associated ophthalmopathy in children and adolescents; J Pediatr Endocrinol Metab; 2016; 29(10): 1115-1122
9. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26(10):1343-1421. doi: 10.1089/thy.2016.0229.
10. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018 Aug;7(4):167-186. doi: 10.1159/000490384.
11. B. Vaidya, A. Wright, J. Shuttleworth, et al. Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves' disease: a retrospective observational study. Clin Endocrinol (Oxf), 81 (2014), pp. 610-613. doi.org/10.1111/cen.12478
12. J. Harvengt, P. Boizeau, D. Chevenne, et al. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications. Eur J Endocrinol, 172 (2015), pp. 715-723. doi.org/10.1530/EJE-14-0959
13. K. Yasuda, Y. Miyoshi, M. Tachibana, et al. Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves' disease. Clin Pediatr Endocrinol, 26 (2017), pp. 1-7. doi: 10.1297/cpe.26.1
14. Azizi F., Takyar M., Madreseh E., Amouzegar A. Long-term Methimazole Therapy in Juvenile Graves' Disease: A Randomized Trial. Pediatrics. 2019 May;143(5). pii: e20183034. doi: 10.1542/peds.2018-3034.
15. Lёger J., Carel JC. MANAGEMENT OF ENDOCRINE DISEASE: Arguments for the prolonged use of antithyroid drugs in children with Graves' disease. Eur J Endocrinol. 2017 Aug;177(2):R59-R67. doi: 10.1530/EJE-16-0938. Epub 2017 Apr 5.
16. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Lёger J; French Childhood Graves' Disease Study Group. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008 Oct;93(10):3817-26. doi: 10.1210/jc.2008-0842.